Forsta AP Fonden Has $36.76 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Forsta AP Fonden increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,450,800 shares of the biopharmaceutical company's stock after acquiring an additional 67,300 shares during the period. Forsta AP Fonden's holdings in Pfizer were worth $36,763,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. Martingale Asset Management L P increased its position in Pfizer by 416.6% during the fourth quarter. Martingale Asset Management L P now owns 127,129 shares of the biopharmaceutical company's stock worth $3,373,000 after buying an additional 102,521 shares during the last quarter. DRW Securities LLC acquired a new position in Pfizer during the fourth quarter worth approximately $877,000. Finally, F M Investments LLC raised its stake in Pfizer by 15.9% in the fourth quarter. F M Investments LLC now owns 94,051 shares of the biopharmaceutical company's stock valued at $2,495,000 after buying an additional 12,895 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE opened at $24.25 on Friday. The company has a market cap of $137.84 billion, a price-to-earnings ratio of 12.90, a PEG ratio of 0.87 and a beta of 0.52. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.96 and a current ratio of 1.16. The stock has a fifty day moving average price of $24.42 and a 200-day moving average price of $24.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 earnings per share. Pfizer's revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Berenberg Bank decreased their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. TD Cowen cut their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. Finally, Leerink Partners decreased their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.